Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

NCT07705334 is registered in ClinicalTrials.gov with SHY Therapeutics as lead sponsor.

NCT NCT07705334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07705334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
SHY Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
June 24, 2026
Completion date
May 15, 2028
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, colon cancer, gastric cancer, hepatecellular carcinoma, hormone refractory prostate cancer, hr+ breast cancer, mesothelioma, nsclc (advanced non-small cell lung cancer), pancreatic carcinoma metastatic, soft tissue sarcomas, triple negative breast cancer (tnbc)